



To: The Copenhagen Stock Exchange

TRANSLATION

**Announcement No. 6 in 2006/07
November 28, 2006**

ALK-Abelló and Menarini sign agreement for co-promotion, distribution and licensing of GRAZAX[®] in certain parts of Europe

Summary: ALK-Abelló A/S and Menarini Group today signed an agreement for co-promotion, distribution and licensing of ALK-Abelló's tablet-based allergy vaccine GRAZAX[®] in a number of European countries.

ALK-Abelló A/S and Menarini Group today signed an agreement for co-promotion, distribution and licensing of ALK-Abelló's tablet-based vaccine against grass pollen allergy GRAZAX[®] and two coming tablet products in development for the European market.

The agreement provides broad European availability of the tablet-based vaccines in areas where ALK-Abelló has a limited presence.

- A. ALK-Abelló and Menarini will co-promote GRAZAX[®] in the UK, Belgium, Ireland and Luxembourg.
- B. Menarini receives exclusive rights to promote, sell and distribute GRAZAX[®] in the following EU countries: Greece, Portugal, Poland, Czech Republic, Hungary, Slovenia, Slovakia, Latvia, Lithuania, Estonia, Cyprus and Malta.
- C. Menarini receives exclusive licensing rights in the non-EU countries Russia, Turkey, Romania, Croatia, Serbia, Bulgaria, Ukraine, Kazakhstan and Belarus. In these countries, Menarini will also handle the national approval procedures.

Under the agreement, Menarini will purchase the products from ALK-Abelló for sales in all the above-mentioned markets. In markets where GRAZAX[®] is co-promoted, the companies will also share the profit proportional to their marketing efforts.

The financial impact of the agreement is included in the forecast for the current financial year, which covers the period September 1 to December 31, 2006.

Hørsholm, November 28, 2006
ALK-Abelló A/S

Jens Bager
President and CEO

For further information please contact:
Jens Bager, President and CEO, +45 4574 7445



About Menarini

The Menarini Group is a privately owned pharmaceutical company headquartered in Florence, Italy. Menarini employs approximately 12,500 employees (hereof two thirds outside Italy) with a strong presence in Western and Eastern Europe, Asia and Central America. Along with products of its own R&D, Menarini has substantial long-term experience with sales and marketing of in-licensed products from a large number of pharmaceutical companies and currently employs more than 2,000 sales representatives in the 25 markets where Menarini receives rights to GRAZAX[®]. In 2005, the Menarini Group generated revenue of EUR 2.2 billion.

About ALK-Abelló

ALK-Abelló is devoted to improving the lives of people with allergies by developing pharmaceutical products that target the cause of their allergic disease. ALK-Abelló is the world leader in the development of immunotherapy treatments – a unique treatment that induces a protective immune response with sustained symptom prevention. Allergy immunotherapy is traditionally conducted as subcutaneous injections or sublingual droplets. ALK-Abelló aims to extend the use of immunotherapy by introducing convenient tablets for home treatment, thereby offering many more patients a causal allergy treatment. ALK-Abelló has more than 1,200 employees with subsidiaries, production facilities and distributors throughout the world. The company is headquartered in Hørsholm, Denmark and listed on the Copenhagen Stock Exchange.

About GRAZAX[®]

GRAZAX[®] is the first allergy tablet that improves patients' quality of life by treating the underlying cause of grass pollen allergy and not just the symptoms. Clinical studies show that GRAZAX[®] has a good safety profile and provides significant efficacy within the first season of treatment. In a global evaluation of patients' perceptions of efficacy of GRAZAX[®] treatment, 82 percent of the patients felt 'better' or 'much better' in the first season of treatment, compared with the previous pollen seasons.

Grass pollen allergy is a health problem representing a significant social burden. At least 45 million people in Europe suffer from grass pollen allergy in the shape of allergic rhinitis (hay fever) or allergic asthma – or both.